Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Casey O'Connell, MD

    TitleAssociate Professor of Clinical Medicine, Lawrence and Janice Kelly Chair in Hematology
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    Address1441 Eastlake Ave.
    Health Sciences Campus
    Los Angeles California 90033
    Phone+1 323 865 3950
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Casey O’Connell is an Associate Professor in the Jane Anne Nohl Division of Hematology at the Keck School of Medicine, University of Southern California (USC). She did her undergraduate work at Stanford University and completed her medical degree with distinction at the George Washington School of Medicine. She began her career as a clinical researcher at USC’s Norris Comprehensive Cancer Center in the area of cancer-related thrombosis by describing the clinical significance of incidental pulmonary embolism identified on routine cancer staging CT scans. Her original work in this area was published in the Journal of Clinical Oncology and brought this clinical entity to the attention of oncologists worldwide. Dr. O’Connell’s background in cancer-related thrombosis has generated a focused interest in Myeloproliferative Neoplasms (MPNs), which include Polycythemia Vera, Essential Thrombocytosis and Myelofibrosis. In addition to leading clinical treatment trials for patients with these malignancies, she pursues translational research seeking to discover how they induce arterial and venous thrombosis. The MPNs and Myelodysplastic syndrome (MDS) are malignant hematopoietic disorders with pleiotropic clinical manifestations. Dr. O’Connell is interested in optimizing the role of epigenetic therapy in these pre-leukemic conditions that can lead to acute myeloid leukemia.

      As director of the new GEHR CURES Myeloid Malignancy Program, Dr. O’Connell is focused on optimizing therapies and on novel ways to intervene earlier to prevent progression of these disorders. Dr. O’Connell is proudest of her accolades for patient care in Southern California and for teaching at the Keck School of Medicine, where she is the Director of the Year II Hematology Course.


      Collapse Biography 
      Collapse Awards and Honors
      Keck School of Medicine2013Master Teacher Distinction
      LAC+USC Medical Center2013Medical Staff Leadership Recognition Award
      Keck School of Medicine 2012  - 2013Outstanding Year I Teaching Award
      Keck School of Medicine2011  - 2012Best Year I System
      Keck School of Medicine 2008  - 2009Outstanding Year I Teaching Award
      Division of Hematology, USC2006  - 2007Fellow Research Award
      Division of Hematology, USC2004  - 2005Fellow Teaching Award
      USC Department of Medicine2003  - 2004Senior Resident of the Year
      USC Department of Medicine2003  - 2004Brautbar Teaching Award
      Keck School of Medicine2003Outstanding Resident Teaching Award
      George Washington University Department of Medicine2001Jorge C. Rios Award in Internal Medicine
      1999Laszlo M Tauber Scholarship
      George Washington University School of Medicine1998William Beaumont Medical Research Honor Society

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Piatek CI, Vergara-Lluri ME, Pullarkat V, Siddiqi IN, O'Connell C, Brynes RK, Feinstein DI. Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome. Acta Haematol. 2017 Sep 02; 138(3):129-137. PMID: 28866671.
        View in: PubMed
      2. Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell C, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Aug 24. PMID: 28844816.
        View in: PubMed
      3. Chiu V, O'Connell C. Management of the Incidental Pulmonary Embolism. AJR Am J Roentgenol. 2017 Mar; 208(3):485-488. PMID: 28004969.
        View in: PubMed
      4. Gardner D, Liman A, Autelli V, O'Connell C, Testa N, Ault G. Initiating a Standard Venous Thromboembolism Prophylaxis Order Set Designed to Improve Patient Outcomes at Los Angeles County+University of Southern California. Am Surg. 2016 Oct; 82(10):1000-1004. PMID: 27779993.
        View in: PubMed
      5. Chow V, Weissman A, O'Connell C, Mehrvar A, Akhtari M. Emerging treatment options for myelofibrosis: focus on pacritinib. Onco Targets Ther. 2016; 9:2655-65. PMID: 27226728; PMCID: PMC4863690.
      6. O'Connell C, Horwood K, Nadamuni M. Correction of refractory thrombocytopenia and anemia following withdrawal of extended release niacin. Am J Hematol. 2016 Jul; 91(7):E318. PMID: 27012809.
        View in: PubMed
      7. Liebman HA, O'Connell C. Incidental venous thromboembolic events in cancer patients: what we know in 2016. Thromb Res. 2016 Apr; 140 Suppl 1:S18-20. PMID: 27067973.
        View in: PubMed
      8. O'Neill C, Siddiqi I, Brynes RK, Vergara-Lluri M, Moschiano E, O'Connell C. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. Ann Hematol. 2016 Apr; 95(5):733-8. PMID: 26961933.
        View in: PubMed
      9. Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110. PMID: 26296954.
        View in: PubMed
      10. O'Connell C. Incidentally found pulmonary embolism: what's the clinician to do? Hematology Am Soc Hematol Educ Program. 2015; 2015:197-201. PMID: 26637721.
        View in: PubMed
      11. O'Connell C. How I treat incidental pulmonary embolism. Blood. 2015 Mar 19; 125(12):1877-82; quiz 2009. PMID: 25533036.
        View in: PubMed
      12. O'Connell C, Liebman HA. Approach to the management of incidental venous thromboembolic events in patients with cancer. J Natl Compr Canc Netw. 2014 Nov; 12(11):1557-60. PMID: 25361802.
        View in: PubMed
      13. Vergara-Lluri ME, Piatek CI, Pullarkat V, Siddiqi IN, O'Connell C, Feinstein DI, Brynes RK. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol. 2014 Nov; 45(11):2183-91. PMID: 25282037.
        View in: PubMed
      14. Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O'Connell C, Solomon SR, Pigneux A, Vey N, Hills R, Jacobsen TF, Gianella-Borradori A, Foss Ø, Vetrhusand S, Giles FJ. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014 Jun 20; 32(18):1919-26. PMID: 24841975.
        View in: PubMed
      15. Piatek C, O'Connell C. Unsuspected pulmonary embolism: impact on mortality among cancer patients. Curr Opin Pulm Med. 2012 Sep; 18(5):406-9. PMID: 22759768.
        View in: PubMed
      16. Piatek C, O'Connell C, Liebman HA. Treating venous thromboembolism in patients with cancer. Expert Rev Hematol. 2012 Apr; 5(2):201-9. PMID: 22475288; PMCID: PMC4435973.
      17. Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R. Experience with pegylated interferon a-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica. 2012 Oct; 97(10):1570-3. PMID: 22419578; PMCID: PMC3487558.
      18. O'Connell C, Razavi PA, Liebman HA. Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism. J Clin Oncol. 2011 Nov 01; 29(31):4208-9; author reply 4209-10. PMID: 21969510.
        View in: PubMed
      19. O'Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, Caton A, Duddalwar V, Boswell W, Grabow K, Liebman HA. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost. 2011 Feb; 9(2):305-11. PMID: 20955348.
        View in: PubMed
      20. Bernstein I, Byun HM, Mohrbacher A, Douer D, Gorospe G, Hergesheimer J, Groshen S, O'Connell C, Yang AS. A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics. 2010 Nov-Dec; 5(8):750-7. PMID: 20861661.
        View in: PubMed
      21. O'Connell C, Liebman HA. Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond. Expert Rev Hematol. 2008 Dec; 1(2):175-82. PMID: 21082922.
        View in: PubMed
      22. O'Connell C, Boswell WD, Duddalwar V, Caton A, Mark LS, Vigen C, Liebman HA. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006 Oct 20; 24(30):4928-32. PMID: 17050877.
        View in: PubMed
      23. O'Connell C, Levine AM. Managing anemia in HIV-positive women. Womens Health (Lond). 2006 Jan; 2(1):159-65. PMID: 19803935.
        View in: PubMed